SCHEMBL3429613

SCHEMBL3429613

OCCN(CCO)C1CC1

nearest known ligand 0.38

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
DRD2 P14416 2/20 0.32
DRD3 P35462 2/20 0.32
DRD4 P21917 1/20 0.32
KCNH2 Q12809 1/20 0.30
CHIT1 Q13231 1/20 0.30
CHIA Q9BZP6 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2484393 1.00 MAPT (0.33) MAPTSLC6A2SLC6A4DRD2DRD3
SCHEMBL1366763 1.00 MAPT (0.33) MAPTSLC6A2SLC6A4DRD2DRD3
SCHEMBL3429371 0.91 OPRM1 (0.35) MAPTSLC6A2SLC6A4DRD2DRD3
SCHEMBL3429155 0.89
SCHEMBL522366 0.88 LTA4H (0.37) SLC6A2SLC6A4
SCHEMBL14609036 0.87
SCHEMBL12961069 0.87 MAPT (0.32) MAPTDRD2DRD3DRD4
SCHEMBL9295854 0.87 DRD3 (0.35) MAPTDRD2DRD3DRD4
SCHEMBL3429609 0.87
SCHEMBL79285 0.86 LTA4H (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116478773-A Airplane cleaning agent and preparation method thereof 广东润和新材料科技有限公司 2023-07-25 CN disclosed
WO-2021078285-A1 CYCLOALKYL-BASED AND HETEROCYCLOALKYL-BASED INHIBITORS, PREPARATION METHOD THEREFOR AND USE THEREOF 苏州泽璟生物制药股份有限公司 2021-04-29 WO disclosed
WO-2021078285-A1 CYCLOALKYL-BASED AND HETEROCYCLOALKYL-BASED INHIBITORS, PREPARATION METHOD THEREFOR AND USE THEREOF 苏州泽璟生物制药股份有限公司 2021-04-29 WO disclosed
WO-2021078312-A1 CYCLOALKYL AND HETERO-CYCLOALKYL INHIBITORS, PREPARATION METHODS THEREFOR, AND USE THEREOF 苏州泽璟生物制药股份有限公司 2021-04-29 WO disclosed
WO-2021078312-A1 CYCLOALKYL AND HETERO-CYCLOALKYL INHIBITORS, PREPARATION METHODS THEREFOR, AND USE THEREOF 苏州泽璟生物制药股份有限公司 2021-04-29 WO disclosed
US-7691867-B2 Chemical compounds ASTRAZENECA AB (SE) 2010-04-06 US disclosed
EP-1613619-B1 QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER ASTRAZENECA AB (SE) 2008-03-26 EP disclosed
US-20060270692-A1 Chemical compounds ASTRAZENECA AB (SE) 2006-11-30 US disclosed
EP-1613619-A1 QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER AstraZeneca AB (SE) 2006-01-11 EP disclosed
WO-2004094410-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2004-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270692-A1 Chemical compounds CCNI, MKI67, TP53 MAPT 2213/4885SLC6A2 2629/4885SLC6A4 3221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.